Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.64 |
| ▸ | PARP1 | P09874 | 1/20 | 0.64 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.64 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.64 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.64 |
| ▸ | GABRP | O00591 | 3/20 | 0.53 |
| ▸ | GABRD | O14764 | 3/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.53 |
| ▸ | GABRE | P78334 | 3/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644987 | 0.82 | CYP1B1 (0.63) | TNKSPARP1TNKS2GABRPGABRD | |
| SCHEMBL1644899 | 0.81 | MAOB (0.60) | TNKSPARP1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1645950 | 0.81 | EGFR (0.54) | TNKSPARP1TNKS2PARP2GABRP | |
| SCHEMBL311324 | 0.81 | NPC1 (0.60) | TNKSCSNK2A2CSNK2BCSNK2A1AR | |
| SCHEMBL13945258 | 0.80 | CYP1A2 (0.56) | TNKSPARP1TNKS2PARP2GABRP | |
| Hydrochloric Acid SCHEMBL1647034 | 0.80 | EGFR (0.52) | TNKSPARP1TNKS2PARP2GABRP | |
| Hydrochloric Acid SCHEMBL1647048 | 0.79 | CYP1A2 (0.55) | TNKSPARP1TNKS2PARP2GABRP | |
| SCHEMBL7568626 | 0.78 | TNKS (1.00) | TNKSPARP1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1645853 | 0.77 | CYP1B1 (0.46) | TNKSPARP1TNKS2PARP2GABRP | |
| SCHEMBL311707 | 0.77 | TNKS (0.63) | TNKSPARP1TNKS2PARP2GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | TNKS 4486/4885PARP1 4272/4885CSNK2A2 2777/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | TNKS 4486/4885PARP1 4272/4885CSNK2A2 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.